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P revention and/or treatment of endophthalmitis following intraocular surgery or trauma is clinically important because of its serious, vision-threatening consequences. [1] [2] [3] Ophthalmologists have commonly used empirical intraocular antibiotics, effective against gram-positive and gram-negative microorganisms, before confirming the results of aqueous and vitreous culture. However, this empirical treatment is ineffective against bacteria resistant to empirical antibiotics or other infectious microorganisms, including fungus and viruses.
Povidone-iodine (PVI) is widely recognized as a bactericidal and virucidal agent that is effective against a variety of common pathogens, including resistant pathogenic microorganisms. 4, 5 Five percent PVI has been used topically as a postoperative and/or preoperative bactericidal prophylactic agent in the eye. 1, [6] [7] [8] The excellent efficacy and broad spectrum activity of PVI against microbial infections has generated interest in its possible intraocular use.
Several studies have demonstrated the tolerance and efficacy of intravitreous PVI injection in animal models. Whitacre and Crokett 9 first reported that a concentration of 0.05 to 0.5% PVI was safe in rabbit eyes. Trost et al. 10 demonstrated that PVI in a concentration of up to 0.4% was tolerable but that intravitreal PVI had no effect against bacterial endophthalmitis. However, Brozou et al. 11 demonstrated that an intravitreal injection of 0.2% PVI could inhibit bacterial endophthalmitis due to Staphylococcus epidermidis, although chronic inflammation in the retinal tissue was detected.
These previous studies did not investigate the pharmacokinetics of intraocular PVI. Tissue toxicity and drug efficacy should be elucidated prior to intraocular use of PVI. If the halflife of the drug in the eye is short, its concentration would not be maintained effectively to treat endophthalmitis; thus, an increase in the drug concentration or repeated injection with a suitable interval would be required to extend the duration of action, regard the balance between tolerance and efficacy.
However, the pharmacokinetics of PVI and the efficacy of repeated PVI injections have not yet been studied.
The aim of this study was to evaluate the pharmacokinetics of PVI in vitreous humor and its effect on S. epidermidis endophthalmitis in rabbit eyes, using single and repeated injections.
METHODS

Animal Model and Experimental Design
Eighty New Zealand white rabbits (Covance, Princeton, NJ, USA), each weighing approximately 2 kg, were used. All procedures were performed in accordance with Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The study was approved by the Pusan National University Yangsan Hospital institutional review board (certification PNUYH 2014-019/24 February 2014).
This study consisted of two phases as follows: Phase I was conducted to elucidate the pharmacokinetics and safety of PVI in the eye, whereas phase II was conducted to determine the efficacy of intravitreal PVI in the treatment of S. epidermidis endophthalmitis. Animals with media opacity that obscured fundoscopic examination or ocular disease were excluded at baseline.
Phase I Study
Forty rabbits were divided into two groups (n ¼ 20 in each group). Group I included rabbits receiving intraviteal 0.1% PVI (0.1 mg/0.1 mL) injections, whereas group II rabbits received 0.3% PVI (0.3 mg/0.1 mL) injections. Povidone-iodine was intravitreally injected into the right eye. All eyes underwent slit-lamp and indirect fundoscopic examinations at baseline, and then 0.5, 1, 2, 6, and 12 hours after PVI injection. At each time point, three rabbits were killed and their vitreous humors were collected after examination. Povidone-iodine concentration in the vitreous humor was calculated using highperformance liquid chromatography (HPLC). Pharmacokinetic analysis of ocular drug concentration-time data was performed using noncompartmental and compartmental analyses. At baseline, 6, and 12 hours after PVI injection, electroretinography (ERG) was conducted in five rabbits in each group.
Phase II Study
Forty rabbits were divided into four groups (n ¼ 10 in each group). All rabbits received 50 colony-forming units (CFU) of S. epidermidis intravitreally in both eyes. When signs of endophthalmitis, including conjunctival injection, chemosis, flare in the anterior chamber, and decreased red reflex, were observed, PVI was administrated in the vitreous cavity after vitreous aspiration. Group A received a single injection of 0.1% PVI and group B a single injection of 0.3% PVI. Groups C and D received intravitreal 0.1% and 0.3% PVI, respectively, 3 times every second day. Fellow eyes receiving sham injection were controls. Slit lamp and fundoscopic examinations were performed daily during the first week and every other day in the second week. Electroretinography, histologic examination, and vitreous cultures for S. epidermidis were conducted at day 14.
Intravitreal Injection
The procedure was performed under sterile conditions, using an operating microscope for visualization. All injection procedures were performed as follows: Rabbits were anesthetized with intramuscular injection of 25 mg/mL tiletamine plus zolazepam (Zoletil, Virbac, France), and ventilated room air. Pupils were fully dilated with 2.5% phenylephrine and 1% cyclopentolate hydrochloride. After instillation of 0.5% proparacaine for topical anesthesia, intravitreal injections were performed using a 30-gauge needle attached to a tuberculin syringe. Anterior chamber paracentesis using a 26-gauge needle was performed prior to intravitreal injection to avoid increased intraocular pressures and to minimize vitreous reflux after injection. The needle was inserted bevel up and 2-mm posterior to the limbus; it was advanced toward the center of the vitreous until the tip could be viewed with an operating microscope. A volume of 0.1 mL was slowly injected. Arterial pulsation around the optic disk was checked using the indirect ophthalmoscope.
Determination of Total Iodine in Eye Samples by High-Performance Liquid Chromatography
Vitreous samples were stored at À208C until used and were allowed to thaw to room temperature before processing. Samples (200 lL) were combined with 50 lL sodium thiosulfate solution (100 lg/mL) in each tube and then mixed by vortexing for 1 minute. Two-hundred fifty microliters of methanol were added to each sample to precipitate the protein by vortexing for 2 minutes. The mixture was centrifuged at 2500g for 10 minutes to remove any precipitated material. The supernatant was assayed by HPLC (Gilson, Middleton, WI, USA). A reverse-phase capcell-pak C 18 column (100 3 4.6 mm; pore size, 5 lm) was used. The mobile phase consisted of a mixture of methanol and water (30:70, v/v) with 6 mmol/L tetrabutylammonium bromide (TBA.Br) as the ion-pair reagent. Flow rate was set at 1.0 mL/min, and the detection wavelength was 223 nm. Curve standards were prepared by dissolving KI in mobile phase. The amount of iodide in the samples was determined from the peak area correlated with the standard curve. The chromatographic run time for each analysis was 12 minutes.
Pharmacologic Data Analysis
Pharmacokinetic analysis of ocular drug concentration-time data was performed using noncompartmental and compartmental analysis (WinNonlin version 3.1 software; Pharsight, Mountain View, CA, USA). Noncompartmental analysis was performed to calculate the following pharmacokinetic parameters: total area under the plasma concentration-time curve from time zero to time infinity (AUC), time-averaged total body clearance (CL), apparent volume of distribution at a steady state (V ss ), and terminal half-life (t 1/2 ). Compartmental analysis was performed to estimate the compartmental volume of distribution (V d ), maximal elimination rate (V max ), and Michaelis-Menten constant (K m ) by fitting the data to the following equation that describes a one-compartment model with Michaelis-Menten elimination kinetics:
where C and t are mean PVI concentration and time, respectively.
Electroretinography ERG responses were recorded using a commercial ERG system (Verice Science version 6.0 EDI; Electro-Diagnostic, Inc., Redwood City, CA, USA). Rabbits were placed in a dark room for 1 hour. Pupils were dilated by instillation of 2.5% phenylephrine and 1% cyclopentolate hydrochloride. Refer-ence and ground electrodes were placed and clipped on the lateral canthus and the earlobe, respectively, after being shaved. Active electrodes (ERG Jet; Fabrinal SA, La Chaux-de-Fonds, Switzerland) were placed on the cornea with Hypromellose (Hycell solution, 2%; Samil Pharm., Seoul, Korea), and the head was positioned in the Ganzfeld dome. Dark-adapted ERG responses were recorded by stimulation with À25 to 0 dB white flashes (increasing by 5 dB; 0.0095-3.004 cd-s/m 2 ). Signals were amplified with a bandpass of 1 to 300 Hz. A decrease in postinjection response over 25% was considered significant.
Histologic Examination
The anterior segment was removed, and a full-thickness specimen including the retina and sclera was obtained at the same distance below the optic disc. Tissues were prefixed with 2.5% glutaraldehyde (at 48C; phosphate buffer, pH 7.2) and were postfixed with 1% osmium tetroxide in the same buffer. Materials were dehydrated with a series of graded ethyl alcohol and were embedded in epoxy resin (Epon 812 mixture). These materials were stained with 1% toluidine blue for light microscopy.
Bacterial Preparation and Quantification
The S. epidermidis strain was incubated overnight in mannitol salt agar (MSA; Difco, Hunt Valley, MD, USA) at 378C. The culture was grown until its concentration reached approximately 50 CFU per mL. A 26-gauge needle was used to inject 50 CFU of S. epidermidis (0.1 mL suspension with a concentration of 500 CFU/mL) directly into the vitreous cavity via the pars plana, 2 mm posterior to the limbus. Quantitative and qualitative vitreous culture was performed at day 14 in the phase II study. Vitreous humors (0.05 mL) were obtained in a sterile manner using a 24-gauge needle with a 1.0-mL syringe.
The specimen was placed on MSA and spread over the agar surface with a sterile bent glass rod. After overnight incubation at 358C, the number of colonies yielded per plate was expressed as CFU per milliliter.
Statistical Analysis
Data are means 6 SD. Amplitudes and implicit times of a-waves and b-waves in ERG were measured and compared between the tested eyes, using the Mann-Whitney U test. All analysis was conducted using SPSS software version 18.0 (SPSS, Inc., Chicago, IL, USA). A P value of <0.05 was considered statistically significant.
RESULTS
Phase I Study
Clinical Examination. Drug-induced ocular complications such as retinal hemorrhage, retinal detachment, optic atrophy, retinal ischemia or infarction, cataracts, corneal opacity, or severe intraocular inflammation were absent in both groups.
Pharmacokinetic Analysis. The mean concentration-time profiles of groups I and II in the vitreous humor are shown in Figure 1 . Relevant pharmacokinetic parameters are listed in the Table. As shown in Figure 1 , nonlinear decay in the log concentration profiles of PVI was observed during the initial 2 hours. In the noncompartmental analysis, the dose increase from 0.1% to 0.3% resulted in an overproportional increase of AUC; the dose-normalized AUC values of groups I and II were 0.222 and 0.478 h/mL, respectively. Moreover, CL and V ss tended to decrease as the dose increased (Table) . These results indicated that vitreous PVI exhibited dose-dependent (nonlinear) pharmacokinetics after ocular injection. Thus, nonlinear Michaelis-Menten kinetics were used to describe the elimination process in the compartmental analysis. The t 1/2 values of the 0.1% and 0.3% PVI in the vitreous were 3.27 and 3.58 hours, respectively. The PVI concentration data was well described by the one-compartment model with single Michaelis-Menten elimination kinetics, and the V d , V max , and K m values were successfully estimated as shown in the Table. Electroretinography. Before and after PVI injection, there were no significant changes in the mean values of a-and b-wave amplitudes at baseline, 6, and 12 hours in groups I and II (Fig. 2) .
Histologic Examination. No retinal damage was noted in either group (Fig. 3 ).
Phase II Study
Clinical Examination and Microbiological Results. All eyes receiving 50 CFU of S. epidermidis displayed obvious signs of endophthalmitis (hyperemic conjunctiva, chemosis, miosis, and vitreous haze) within 24 to 48 hours. Endophthalmitis was confirmed to detect S. epidermidis in the aspirated Control eyes showed manifestations of severe bacterial endophthalmitis including chemosis and severe vitreous opacity at day 14 ( Fig. 4) .
Of 10 eyes, 4 eyes (receiving 20, 60, 60, and 70 CFU) and 3 eyes (receiving 20, 40, and 60 CFU) demonstrated S. epidermidis growth in vitreous samples in groups A and B at day 14, respectively. However, there was no bacterial growth in groups C and D. The control group had bacterial growth of 5,500 6 550 CFU (average) in all eyes.
Electroretinography. Figure 5 shows representative ERG waves at day 14. Electroretinography waves were not recordable in all eyes of the control group. There were statistically significant differences in amplitudes of the a-wave at À5 to 0 dB between eyes given a single PVI injection (groups A and B) and eyes that received repeated PVI injections (groups C and D). The b-waves in groups A and B showed a significant decrease in amplitudes at all intensities, compared to groups C and D (Fig. 6) .
Histologic Examination. Groups A and B had more prominent retinal damage, including lymphocyte infiltration in the inner retinal layers, than that in Groups C and D, which showed minimal inflammatory change (Fig. 7) . Control eyes demonstrated severe inner retinal damage with destructive tissue changes.
DISCUSSION
Intravitreal use of PVI was first reported by Whitacre and Crokett. 9 In their study, PVI at concentrations of 0.05 to 0.5% did not produce any notable retinal damage, although one eye had mild vitritis after 0.5% PVI injection. However, 5.0% PVI induced severe retinal damage in all eyes. They concluded that PVI concentrations between 0.05% and 0.5% would be tolerable in the eyes. Trost et al. 10 confirmed a safety threshold of up to 0.4% PVI. Additionally, they identified the ineffective-ness of a single 0.1% PVI injection for S. epidermidis endophthalmitis, 10 and concluded that intraocular PVI was not a useful treatment for bacterial endophthalmitis. However, this result could mostly be attributable to the single injection as well as low concentration (0.1%). This hypothesis was supported by the work of Brozou et al., 11 who showed that S. epidermidis endophthalmitis improved after a 0.2% PVI injection.
Based on previous results, we selected 0.1% and 0.3% concentrations of PVI for evaluation in this study. Electroretinographs and histologic examination of the retina confirmed that both 0.1% and 0.3% PVI were tolerable in the phase I study. Considering the t 1/2 determined in the phase I study, we administrated PVI into the vitreous every second day for repeated injections in the phase II study.
Well-known limitations of intraocular drug use include the short duration of action owing to its use at a low concentration to achieve efficacy and avoid toxicity; the efficacy of drug is directly related to the concentration achieved, which also correlates with the degree of tissue damage. Thus, repeated injections are a common method to treat intraocular disease, infection, and inflammation. For example, the regular injection of antivascular endothelial growth factor agent is widely accepted for the treatment of wet age-related macular degeneration and diabetic macular edema. [12] [13] [14] [15] In cases of endophthalmitis, the standard care is intravitreal drug administration with or without surgical treatment. 16 Repeated injections of antibiotics are occasionally administered in cases that do not fully recover after a single injection of the drug. In such cases, efficacy and safety have been proven in previous studies. 17, 18 Thus far, the half-life of various antimicrobial and antifungal agents have been reported to be from 0.5 to 30 hours. 19 The present study showed that single use of 0.1% PVI did not have any beneficial effect on endophthalmitis, which correlates with the results of previous studies, whereas repeated injections of 0.1% PVI were found to be effective. Moreover, repeated injections achieved better results in the vitreous culture for bacterial growth, ERG, and histology than a single PVI injection with high concentration (0.3%). Both repeated injection of 0.1% and 0.3% PVI did not differ in the treatment of S. epidermidis endophthalmitis. Our results demonstrated that PVI could have a beneficial effect in treating bacterial endophthalmitis by using repeated injections regard of its 3-hour half-life, even at a low concentration. Moreover, it is well known that PVI has an additional advantage as a broadspectrum agent against microorganisms, compared to antibiotics.
There are some limitations to this study. First, it is based on an animal model and the study was designed to investigate short-term changes. Response to intraocular infections and subsequent treatment in rabbits may differ from that in humans. Thus, our results from this experimental animal model may not reflect the clinical course in humans directly. Second, this study could lack sufficient power to detect the beneficial effects of PVI on bacterial counts in the vitreous due to the small number of animals used. A larger number of animals tested could generate a different outcome. Finally, it is most likely that similar results would not be observed if we altered the types of bacteria, size of the inoculation, and timing of the treatment.
In conclusion, PVI has a 3-hour half-life in the vitreous. Both 0.1% and 0.3% PVI can be tolerated in rabbit eyes. Repeat injections of intravitreal PVI could be effective for the treatment of S. epidermidis endophthalmitis, even at a low concentration. Further investigation of intraocular PVI use should be conducted for the treatment of various pathogens causing endophthalmitis.
